VivoSeq
Immunology

Cutaneous Lupus Erythematosus

32

Pipeline Programs↗

8

Active Trials↗

20

Companies Involved↗

Cutaneous Lupus Erythematosus is a moderately active landscape with 32 programs across 20 companies. The most active players are Pfizer, GSK, Kyowa Kirin Co., Ltd.. 2 therapies are approved with 5 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

54/100

Pipeline Velocity

19/100

Mech. Concentration

20/100

Completion Rate

70/100

Attrition Rate

21/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Pfizer logo

Pfizer

1 program

Phase 1GSK logo

GSK

1 program

Phase 1Kyowa Kirin Co., Ltd. logo

Kyowa Kirin Co., Ltd.

1 program

Phase 1Argenx logo

Argenx

1 program

Phase 1Sanofi logo

Sanofi

1 program

Phase 2V

Ventus Therapeutics U.S., Inc.

1 program

Phase 2

Pipeline

Programs by Phase

Analysis

Modality Breakdown

94%

Small molecule

31 of 33 classified programs — the dominant modality here.

6%ALL OTHERSMonoclonal antibody26%

Small molecule leads; the ring shows all 33 classified programs, each share of the total. Modality classified for 100% of 33 pipeline programs.

Analysis

Trial Status

28

clinical trials

Completed14 · 50%
Terminated5 · 18%
Recruiting3 · 11%
Not yet recruiting2 · 7%
Active, not recruiting2 · 7%
Enrolling by invitation1 · 4%
Other1 · 4%

Clinical Trials

Trial Activity

28 trials

A Study to Continue the Administration of Deucravacitinib in Participants With Systemic Lupus Erythematosus (SLE) or Discoid and/or Subacute Cutaneous Lupus Erythematosus (DLE/SCLE) Who Have Completed Study IM011074 or Study IM011132
Recruiting·Bristol-Myers Squibb logoBristol-Myers Squibb·Phase 4·NCT06875960·35 enrolled
Deep Phenotyping of Cutaneous Lupus Erythematosus
Recruiting·CCentre for Human Drug Research, Netherlands·N/A·NCT06411106·40 enrolled
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2a Study With an Open-Label Extension Evaluating the Efficacy and Safety of VENT-03 in Adult Participants With Active Cutaneous Lupus Erythematosus With or Without Systemic Lupus Erythematosus
Recruiting·VVentus Therapeutics U.S., Inc.·Phase 2·NCT07260877·24 enrolled
A Study of KK4277 in Healthy Volunteers and Patients With Systemic Lupus Erythematosus and Cutaneous Lupus Erythematosus
Active, not recruiting·Kyowa Kirin Co., Ltd. logoKyowa Kirin Co., Ltd.·Phase 1·NCT05411016·157 enrolled
A Study to Evaluate Efficacy and Safety of Deucravacitinib in Participants With Active Discoid and/or Subacute Cutaneous Lupus Erythematosus (DLE/SCLE)
Active, not recruiting·Bristol-Myers Squibb logoBristol-Myers Squibb·Phase 2·NCT04857034·74 enrolled
Evaluate the Efficacy and Safety of ICP-488 in Subjects With Cutaneous Lupus Erythematosus (CLE) Double-blind Study
Not yet recruiting·BBeijing InnoCare Pharma Tech Co., Ltd.·Phase 2·NCT07440537·105 enrolled
Lenalidomide vs Methotrexate in Difficult-to-treat Cutaneous Lupus Erythematosus
Not yet recruiting·AAssistance Publique - Hôpitaux de Paris·Phase 3·NCT06965244·122 enrolled
Tapinarof for Cutaneous Lupus Erythematosus
Enrolling by invitation·NNorthwestern University·Phase 1·NCT06661213·10 enrolled
Study to Evaluate Safety and Efficacy of Filgotinib and Lanraplenib in Females With Moderately-to-Severely Active Cutaneous Lupus Erythematosus (CLE)
Completed·Gilead logoGilead·Phase 2·NCT03134222·47 enrolled
IVIg Efficacy Study to Treat Cutaneous Lupus Erythematosus
Completed·UUniversity of California, Irvine·Phase 1·NCT01841619·16 enrolled
Proof of Concept Study of SAR443122 in Patients With Cutaneous Lupus Erythematosus
Completed·Sanofi logoSanofi·Phase 2·NCT04781816·78 enrolled
A Study to Assess the Safety and Drug Levels of BMS-986256 in Participants With Active Cutaneous Lupus Erythematosus
Completed·Bristol-Myers Squibb logoBristol-Myers Squibb·Phase 1·NCT04493541·13 enrolled
To Evaluate the Preliminary Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of CC-11050 in Subjects With Discoid Lupus Erythematosus and Subacute Cutaneous Lupus Erythematosus
Completed·Amgen logoAmgen·Phase 2·NCT01300208·48 enrolled
A Study of the Safety and Pharmacokinetics of CNTO 136 in Patients With Cutaneous Lupus Erythematosus and Systemic Lupus Erythematosus
Completed·CCentocor Research & Development, Inc.·Phase 1·NCT01702740·49 enrolled
Evaluation of Lenalidomide (REVLIMID®) to Treat Subjects With Cutaneous Lupus Erythematosus (CLE)
Completed·UUniversity of Pennsylvania·N/A·NCT00633945·5 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)